Why is a waiver of non-compete restrictions necessary?

It allows directors to perform their duties in group companies without being constrained by legal conflicts of interest.

What is this news about?

It is an announcement that YongHoon Biotech formally approved the waiver of non-compete restrictions for its directors at a shareholders' meeting.

Is there investment in the Chinese business mentioned?

Yes, an investment of approximately 1.06 million RMB by Lee Fang-Chuan in Dequan Pharmaceutical (Jiangsu) Co., Ltd. is disclosed.

AI News NQ Analysis

[YongHoon Biotech] Shareholders' meeting approves waiver of non-compete restrictions for new directors

NQ Score 70/100

N1 Content Completeness 5

AI Summary (NQ-processed)

On May 22, 2026, YongHoon Biotech passed a resolution at its annual shareholders' meeting to waive non-compete restrictions for directors, including Lee Fang-Chuan. This action regularizes their dual roles in Chinese operations, with no significant financial impact reported.

AI Analysis

Frequently Asked Questions

Q: Why is a waiver of non-compete restrictions necessary?: A: It allows directors to perform their duties in group companies without being constrained by legal conflicts of interest.
Q: What is this news about?: A: It is an announcement that YongHoon Biotech formally approved the waiver of non-compete restrictions for its directors at a shareholders' meeting.
Q: Is there investment in the Chinese business mentioned?: A: Yes, an investment of approximately 1.06 million RMB by Lee Fang-Chuan in Dequan Pharmaceutical (Jiangsu) Co., Ltd. is disclosed.